Xequel Bio

📍 Fort Worth, United States👥 16 employees💰 Last funded Jul 2019
Biotechnology Research🌐 xequel.com
Website LinkedIn
Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body’s response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. The Company’s lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Xequel Bio?
Xequel Bio has 1 investors on record on gritt.io.
When did Xequel Bio last raise funding?
The most recent investment in Xequel Bio recorded on gritt.io was in July 2019.
What industry is Xequel Bio in?
Xequel Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Xequel Bio based?
Xequel Bio is headquartered in Fort Worth, United States.